Please try another search
For the three months ended 31 March 2020, Tetraphase Pharmaceuticals Inc revenues increased 38% to $1.8M. Net loss decreased 38% to $12.1M. Revenues reflect Product revenue, net increase from $341K to $1.8M. Lower net loss reflects Research and development - Other decrease of 69% to $1.8M (expense), Stock-based Compensation in SGA decrease of 79% to $374K (expense), General and administrative - Other decrease of 11% to $10.3M (expense).
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Revenue | 1.75 | 1.69 | 3.34 | 1.07 |
Gross Profit | 0.3 | 0.26 | 2.36 | 0.67 |
Operating Income | -12.26 | -11.54 | -15.91 | -22.61 |
Net Income | -12.12 | -11.37 | -16.3 | -22.92 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Total Assets | 37.35 | 36.38 | 42.28 | 90.08 |
Total Liabilities | 9.9 | 13.22 | 15.67 | 48.33 |
Total Equity | 27.45 | 23.17 | 26.61 | 41.74 |
Period Ending: | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -11.15 | -63.67 | -52.73 | -36.76 |
Cash From Investing Activities | 0.13 | 0.48 | -0.1 | -0.11 |
Cash From Financing Activities | 15.93 | -23.34 | -30.44 | 0.04 |
Net Change in Cash | 4.91 | -86.54 | -83.27 | -36.82 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review